Substance-Related Disorders study with SNP/CNV (Array) data on dbGaP (1,816 participants)

phs003558 — Genomics of Substance Use Disorders in Latin American Populations

<p>This is a subsample of the National Survey of Drug, Alcohol, and Tobacco Use, administered in 2016 between August and October to participants aged 12-65 in urban and rural Mexican households, named Mexican Genomic Database for Addiction Research (MxGDAR). The objective of the survey was to evaluate the patterns of use of different psychoactive substances and mental health problems in Mexico. The sample universe was made up of primary sampling units (PSUs) that were the sum of basic statistical geographic areas, stratified by state and urban-rural communities. An adult aged 18-65 was chosen randomly from each household, and an adolescent aged 12-17 was also chosen randomly from the household which has at least one member under 18. The second administration of the survey included a subsample of 13,130 respondents who agreed to give a saliva sample for DNA analysis, to be used in analyzing the relationship of mental health, addiction, and genetics. This sample was weighted according to selection probability to be representative on the national level. Mental health symptomatology for these individuals was evaluated using the <a>Diagnostic Interview for Psychosis and Affective Disorders (DI-PAD)</a> using the operational criteria for psychotic disorders (OPCRIT v.4.0), administered by interviewers trained in its use. It includes the evaluation of symptomatology of psychosis, depression, anxiety, obsession/compulsion, mania/hypomania, and post-traumatic stress. The study seeks to replicate genetic associations with substance use (<a href="https://www.ncbi.nlm.nih.gov/gene/?term=285768">LINC01622</a>), psychiatric disorders (<a href="https://www.ncbi.nlm.nih.gov/gene/5797">PTPRM</a>), or comorbidity between both (<a href="https://www.ncbi.nlm.nih.gov/gene/4255">MGMT</a>) reported in following paper: <a href="https://pubmed.ncbi.nlm.nih.gov/33762635/">https://pubmed.ncbi.nlm.nih.gov/33762635/</a>. Funding for genotyping was provided by the <a href="https://nida.nih.gov/">National Institute on Drug Abuse</a> (NIDA), one of the <a href="https://www.nih.gov/">National Institutes of Health</a> (NIH). </p>